Tom Frohlich

Biotech Executive

Tom Frohlich is a seasoned life sciences executive who recently joined the board of directors at Nested Therapeutics, a biotechnology company focused on developing precision medicine therapies for cancer.1 2 Here are some key details about Tom Frohlich:

Professional Experience

Leadership Experience: Frohlich brings over 25 years of leadership experience across multinational pharmaceutical and emerging biotech companies.1
Co-founder and COO: He co-founded Chinook Therapeutics in 2019 and served as its Chief Operating Officer until the company's $3.5 billion acquisition by Novartis in August 2023.2
Business Development: Prior to Chinook, he was Vice President of Business Development at Arbutus Biopharma, where he played a key role in multiple transactions, including the merger of Tekmira/Oncore and the spin-out of Genevant.1
International Experience: Frohlich has worked internationally at Johnson & Johnson and Merck, leading commercial strategy across all stages of product development, including global launches of telaprevir and STELARA® (ustekinumab).1

Education and Expertise

Educational Background: Frohlich holds a B.Sc. in biochemistry from the University of Victoria and an MBA from the University of Oxford.1 2
Industry Involvement: He has been associated with Versant Ventures, a healthcare investment firm, serving as an operating principal and entrepreneur-in-residence since 2018.1

Current Roles

Board Member: In addition to his role at Nested Therapeutics, Frohlich serves on the board of Borealis Biosciences.3
Life Sciences BC: He is also involved with Life Sciences British Columbia, contributing his expertise to the organization.3

Tom Frohlich's appointment to the board of Nested Therapeutics is seen as a valuable addition, bringing his extensive experience in biotech entrepreneurship, operational expertise, and commercial strategy to support the company's growth and development of innovative cancer therapies.1 4